SCHEMBL4477873

SCHEMBL4477873

COc1ccc2c(c1)OCC(=O)N2Cc1cc(Cl)cc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
SLC5A1 P13866 3/20 0.44
SLC5A2 P31639 3/20 0.44
BRD4 O60885 1/20 0.42
CBX7 O95931 1/20 0.42
CDYL2 Q8N8U2 1/20 0.42
CDYL Q9Y232 1/20 0.42
CDY1; CDY1B Q9Y6F8 1/20 0.42
ALOX15 P16050 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMPD1 P17405 1/20 0.40
TSHR P16473 1/20 0.40
PARK7 Q99497 1/20 0.39
F10 P00742 2/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479986 0.90 L3MBTL1 (0.59) L3MBTL1SLC5A1SLC5A2BRD4CBX7
SCHEMBL4477885 0.83 L3MBTL1 (0.52) L3MBTL1BRD4CBX7CDYL2CDYL
SCHEMBL13973048 0.82 SLC5A1 (0.45) L3MBTL1SLC5A1SLC5A2BRD4TSHR
SCHEMBL13960736 0.80 L3MBTL1 (0.48) L3MBTL1SLC5A1SLC5A2BRD4CBX7
SCHEMBL6096108 0.78 L3MBTL1 (0.72) L3MBTL1SLC5A1SLC5A2BRD4CBX7
SCHEMBL22407571 0.77 L3MBTL1 (0.60) L3MBTL1SLC5A1SLC5A2BRD4CBX7
SCHEMBL4475776 0.77 L3MBTL1 (0.46) L3MBTL1CBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL15176632 0.77 L3MBTL1 (0.70) L3MBTL1BRD4ALDH1A1SMPD1F10
SCHEMBL6096494 0.77 L3MBTL1 (0.70) L3MBTL1BRD4CBX7CDYL2CDYL
SCHEMBL8556616 0.76 TSHR (0.65) L3MBTL1BRD4CBX7CDYL2CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476675-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
US-7476675-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
EP-1603880-B1 QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2008-05-07 EP disclosed
EP-1603880-A1 QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-12-14 EP disclosed
US-20050261308-A1 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC 2005-11-24 US disclosed
US-6943169-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2005-09-13 US disclosed
WO-2004080969-A1 QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2004-09-23 WO disclosed
US-20040186092-A1 Quinolinone derivaties and uses thereof ROCHE PALO ALTO LLC 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186092-A1 Quinolinone derivaties and uses thereof NQO2, UGT1A8, UGT1A1 L3MBTL1 4557/4885SLC5A1 409/4885SLC5A2 983/4885
US-20050261308-A1 Quinolinone derivatives and uses thereof RECQL, NQO2, QRFPR L3MBTL1 4043/4885SLC5A1 1260/4885SLC5A2 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.